Affiliations 

  • 1 Department of Urology, the Third Medical Center, Chinese PLA General Hospital, Beijing, China. drxuys@163.com
  • 2 Department of Urology, the Third Medical Center, Chinese PLA General Hospital, Beijing, China. urolancet@126.com
  • 3 Department of Urology, the Third Medical Center, Chinese PLA General Hospital, Beijing, China. baojun40009@126.com
  • 4 Department of Urology, the Third Medical Center, Chinese PLA General Hospital, Beijing, China. Guliangyouyd1@126.com
  • 5 Department of Urology, the Third Medical Center, Chinese PLA General Hospital, Beijing, China. tjgaoyu@163.com
  • 6 Department of Urology, the Third Medical Center, Chinese PLA General Hospital, Beijing, China. kevinvan2000@163.com
  • 7 Department of Urology, the Third Medical Center, Chinese PLA General Hospital, Beijing, China. yzydxd@163.com
  • 8 Urology unit, Surgery Department, UKM Medical Centre, Kuala Lumpur Malaysia . xenginn@gmail.com
  • 9 Department of Urology, the Third Medical Center, Chinese PLA General Hospital, Beijing, China. urologist@foxmail.com
  • 10 Department of Urology, the Third Medical Center, Chinese PLA General Hospital, Beijing, China. xzhang@tjh.tjmu.edu.cn
Urol J, 2021 Oct 04;18(6):618-622.
PMID: 34606083 DOI: 10.22037/uj.v18i.6629

Abstract

PURPOSE: To compare the treatment outcomes of robotic retroperitoneal lymph node dissection (R-RPLND) versus laparoscopic RPLND (L-RPLND) for clinical stage I non-seminomatous germ cell testicular tumors (NSGCTs).

MATERIALS AND METHODS: We retrospectively reviewed the data of patients with stage I NSGCTs who underwent robotic or laparoscopic RPLND between 2008 and 2017. Perioperative data and oncologic outcomes were reviewed and compared between the two groups. Progression-free survival was analyzed using Kaplan-Meier survival curves and compared between two groups.

RESULTS: A total of 31 and 28 patients underwent R-RPLND and L-RPLND respectively. The preoperative characteristics of the patients were comparable in the two groups. Patients in R-RPLND group had significantly shorter median operative time (140 vs. 175 minutes, P < .001), a shorter median duration to surgical drain removal (2 vs. 4 days, P = .002) and a shorter median postoperative hospital stay (5 vs. 6 days, P = .001). There were no statistical differences in intra- and post-operative complication rate between the groups and the oncologic outcomes were similar in the two groups.

CONCLUSION: In expert hands, R-RPLND and L-RPLND were comparable in oncological parameter and morbidity rate; R-RPLND showed superiority in operation duration, median days to surgical drain removal and postoperative hospital stay for stage I NSGCTs. Multicenter and randomized studies with good power of study and sufficient follow-up duration are required to validate our result.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.